Pharminox and CRT sign TSTA R&D accord
UK-based biopharmaceutical company Pharminox, a developer of small-molecule drugs, says it has signed a deal with fellow UK firm Cancer Research Technology securing the rights to a preclinical oncology program developing telomere signalling targeting agents.
Under the terms of the accord, Pharminox has an exclusive 12-month option to license worldwide development and commercializtion rights to drug candidates identified by the program. The first compound, RHPS4 which demonstrated potent antitumor activity, has already been selected by Pharminox for preclinical assessment. Financial details of the agreement were not made public.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze